RCM
SYRE icon

RA Capital Management’s Spyre Therapeutics SYRE Stock Holding History

RA Capital Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$81.8M Hold
1,621,620
– – 0.87% 26
2025
Q4 		$53.1M Buy
+1,621,620
New +$42.4M 0.54% 34
2022
Q4 		– Sell
-418
Closed -$5K – 82
2022
Q3 		$5K Buy
+418
New +$5.16K ﹤0.01% 81
2016
Q4 		– Sell
-13,445
Closed -$2.15M – 33
2016
Q3 		$2.15M Sell
13,445
-7,417
-36% -$1.03M 0.22% 28
2016
Q2 		$2.54M Buy
+20,862
New +$4M 0.35% 28

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

RA Capital Management's SYRE Position: Q1 2026 in Review

RA Capital Management held its Spyre Therapeutics (SYRE) position steady in Q1 2026 at 1,621,620 shares worth $81.8M. The position accounts for 0.87% of the portfolio, ranked #26.

RA Capital Management first reported a position in SYRE in Q2 2016 and has held it in 5 quarters since. 197 funds tracked by Wall St. Rank hold SYRE as of Q1 2026.

  • RA Capital Management held 1,621,620 shares of Spyre Therapeutics worth $81.8M as of Q1 2026.
  • RA Capital Management left its Spyre Therapeutics share count unchanged in Q1 2026.
  • Spyre Therapeutics made up 0.87% of RA Capital Management's portfolio in Q1 2026, its #26 holding.
  • RA Capital Management first reported a position in Spyre Therapeutics in Q2 2016 and has held it in 5 quarters since.
  • 197 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2026.

Based on RA Capital Management's 13F filing for Q1 2026, filed 15 May 2026.